Literature DB >> 10475366

Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy.

X J Yang1, K Lecksell, S R Potter, J I Epstein.   

Abstract

OBJECTIVES: With increased screening for prostate cancer, we have noted a greater number of patients with small foci of Gleason score 7 or greater prostate cancer on needle biopsy. The significance of these findings is unknown.
METHODS: We studied 57 men with small foci of Gleason score 7 or greater on needle biopsy. Tumor length was less than 1.5 mm in all but 2 cases. In those 2 cases, there were two minute (less than 0.5 mm) foci of cancer separated by 1.8 mm. The length of cancer ranged from 0.2 to 1.8 mm (mean 0.63 mm). In all cases, only one core was involved.
RESULTS: Thirty-three men underwent radical prostatectomy (RP), 14 received radiation, 8 underwent surveillance, and 2 received hormonal therapy. Men who underwent RP were younger (62 years) than those who had radiotherapy (69.1 years), who were younger than those who underwent surveillance (74.5 years). The mean prostate-specific antigen (PSA) for men undergoing RP was 8.0 ng/mL (range 1.4 to 22). Preoperative serum PSA values did not predict organ-confined status. Needle biopsy grades were as follows: 3 + 4 = 7 (n = 30); 4 + 3 = 7 (n = 17); 4 + 4 = 8 (n = 7); 5 + 4 = 9 (n = 1); and 5 + 5 = 10 (n = 2). We were able to review slides in 27 of the RP specimens, of which 24 were well sampled. Of these 24 cases, 33% had positive margins and 33% were not organ confined; the median tumor volume was 0.5 cc (mean 1.04). No difference in RP tumor volume was found between tumors with needle biopsy Gleason primary grade 3 and those with 4 or greater. The percentage of Gleason pattern 4 on needle biopsy weakly correlated with the percentage of Gleason pattern 4 in the RP specimen (P = 0.04). However, the percentage of Gleason pattern 4 only in the RP specimen, but not in the biopsy, correlated with whether the tumor was organ confined.
CONCLUSIONS: The likelihood of having organ-confined disease with small foci of Gleason score 7 or greater on needle biopsy appears to be equivalent to that calculated from the Partin Tables for greater amounts of Gleason score 6 cancer on needle biopsy. In men who are considering RP, small foci of Gleason score 7 or greater adenocarcinoma on needle biopsy should not necessarily be considered an adverse finding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475366     DOI: 10.1016/s0090-4295(99)00166-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance.

Authors:  Rodolfo Montironi; Roberta Mazzucchelli; Theodorus Kwast
Journal:  Virchows Arch       Date:  2003-01-16       Impact factor: 4.064

2.  High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy.

Authors:  Alcides Chaux; Daniel A Fajardo; Nilda Gonzalez-Roibon; Alan W Partin; Mario Eisenberger; Theodore L DeWeese; George J Netto
Journal:  Urology       Date:  2011-12-14       Impact factor: 2.649

Review 3.  Diagnostic accuracy of prostate needle biopsy.

Authors:  Timothy Donahue; Judd Moul
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862

4.  Identifying Clinically Significant Prostate Cancers using 3-D In Vivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation.

Authors:  Mark L Palmeri; Tyler J Glass; Zachary A Miller; Stephen J Rosenzweig; Andrew Buck; Thomas J Polascik; Rajan T Gupta; Alison F Brown; John Madden; Kathryn R Nightingale
Journal:  Ultrasound Med Biol       Date:  2016-03-03       Impact factor: 2.998

5.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.